QSAM Bioscience, Inc. (f/k/a Q2Earth. Inc.) holds the worldwide license for CycloSam (Samaium-153 DOTMP), a clinical stage novel radiopharmaceutical meant to treat different types of bone cancer and related diseases. This nuclear technology uses low specific activity Samarium-153 (resulting in far less europium) and DOTMP, a chelator which is believed to eliminate off-target migration and targets high bone turn over making it an ideal agent to treat osteosarcoma, bone metastases and to perform bone marrow ablation. Sm-153 DOTMP has been cleared by the FDA under an investigator initiated IND to commence human dosing of cancer patients.
AEterna Zentaris Inc is a specialty biopharmaceutical company. It is involved in the development and commercialization of novel pharmaceutical therapies, drug development activities and promotion of products for others in oncology, endocrinology and women's health. The company focuses on the acquisition of licenses to products that are relevant to their therapeutic areas of focus. Its primary product is Apifiny. It is developing Macrilen, Zoptrex and AEZS drugs in the pipeline. https://www.zentaris.com/